A skin anti-inflammatory soothing composition, its method of preparation and use

Abstract

The present application relates to the cosmetic technical field, disclose a kind of skin anti-inflammatory soothing composition and its preparation method and application.The composition of the present application, by the synergistic effect between the water extract of leucodendron and dipotassium glycyrrhizinate, the anti-inflammatory soothing effect of the composition on skin can be improved.In addition, the present application is improved by special improvement to conventional water extraction method, which is beneficial to the directional enrichment of anti-inflammatory soothing active ingredients in leucodendron, improves the anti-inflammatory soothing effect of leucodendron water extract itself, and enhances the synergistic effect between dipotassium glycyrrhizinate.

Description

Technical Field

[0001] This invention relates to the field of cosmetic technology, and in particular to a skin anti-inflammatory and soothing composition, its preparation method, and its application. Background Technology

[0002] As the body's first line of defense against external damage, the skin is frequently subjected to complex inflammatory responses induced by physical stimuli, chemical damage, or microbial invasion. This pathological process typically exhibits a cascade characteristic consisting of "upstream signal activation, midstream signal transduction, downstream factor release, and terminal oxidative damage." Specifically, this manifests as damage to the skin's stratum corneum barrier, abnormal activation of signaling pathways such as NF-κB and MAPK, leading to the excessive secretion of pro-inflammatory factors such as IL-1β, TNF-α, and IL-6, accompanied by histamine release, excessive activation of TRPV1 receptors, and the massive production of free radicals (ROS). These factors ultimately result in skin problems such as redness, itching, burning, and sensitivity, severely impacting skin health and appearance.

[0003] However, commonly used anti-inflammatory and soothing ingredients in the cosmetics industry still have significant shortcomings in practical applications. Most ingredients have relatively simple mechanisms of action, often only inhibiting some inflammatory factors and failing to effectively cover the entire inflammatory pathway. *Chimonanthus salicifolius* SY H, a semi-evergreen shrub belonging to the genus *Chimonanthus* of the family Calycanthaceae, is rich in chemical components, mainly volatile oils, alkaloids, flavonoids, and polysaccharides. Patent CN116370511A found in cellular experiments that *Chimonanthus salicifolius* volatile oil can enhance the cellular activity of LPS-induced THP-1 macrophage inflammation and reduce intracellular ROS and Ca2+. 2+ While it enhances mitochondrial membrane potential, it also suffers from the limitation of having a single anti-inflammatory mechanism. Furthermore, research on the anti-inflammatory and soothing effects of willow-leaf wintersweet extract on the skin is currently lacking, and its application development is insufficient. Further research on its related bioactivity and mechanism of action is urgently needed. Summary of the Invention

[0004] To address the limited efficacy of existing anti-inflammatory and soothing ingredients, this invention provides a skin anti-inflammatory and soothing composition. In this composition, the synergistic effect between the aqueous extract of *Chimonanthus praecox* and dipotassium glycyrrhizate enhances the composition's anti-inflammatory and soothing effects on the skin.

[0005] This invention also provides a method for preparing a skin anti-inflammatory and soothing composition. Compared with conventional water extraction methods, the preparation method of this invention is beneficial for the targeted enrichment of anti-inflammatory and soothing active ingredients in *Chimonanthus praecox*, which not only enhances the anti-inflammatory and soothing efficacy of the *Chimonanthus praecox* water extract itself, but also improves the synergistic effect between the *Chimonanthus praecox* water extract and dipotassium glycyrrhizate.

[0006] The specific technical solution of this invention is as follows: In a first aspect, the present invention provides a skin anti-inflammatory and soothing composition comprising a water extract of *Chimonanthus praecox* and dipotassium glycyrrhizate in a mass ratio of 1 to 3:1; wherein the water extract of *Chimonanthus praecox* is extracted from the leaves and / or stems of *Chimonanthus praecox*.

[0007] This invention has discovered that, in terms of skin anti-inflammatory and soothing effects, the combination of water extract of *Chimonanthus praecox* and dipotassium glycyrrhizate can achieve synergistic effects at the target site. The specific mechanism is as follows: (1) Synergistic effect of ligand-receptor dual interception: Dipotassium glycyrrhizate, as a specific inhibitor of HMGB1, can accurately capture and neutralize this endogenous danger signal, blocking its binding to receptors on the surface of immune cells and cutting off the emission end of inflammatory signals at the source; while the water extract of *Chimonanthus praecox* acts on the signal receiving and transduction end, intercepting transduction pathways that escape or are activated by other danger signals by regulating the TLR4 receptor and its mediated NF-κB / MAPK signaling pathway. The two approach the problem from the two dimensions of ligand neutralization and receptor blocking, respectively, forming a three-dimensional defense system of simultaneous interception, making the anti-inflammatory and soothing effect more thorough and stable.

[0008] (2) Synergistic effect of midstream oxidative damage inhibition and downstream symptom relief: The aqueous extract of *Chimonanthus praecox* can effectively inhibit ROS generation in tissues, reduce oxidative stress damage to skin tissues, and regulate TRPV1 receptor activity to relieve discomfort such as burning and pain. Dipotassium glycyrrhizate focuses on relieving downstream symptoms of inflammation. By inhibiting hyaluronidase activity, it blocks mast cell degranulation and histamine release, significantly relieving skin itching and allergic reactions. At the same time, it helps to downregulate the expression of pro-inflammatory factors, including TNF-α, IL-1β and IL-6, further reducing the inflammatory response. The combination of the two can not only solve the core problem of oxidative damage in the inflammatory process, but also quickly relieve symptoms such as skin redness, itching and burning.

[0009] Secondly, the present invention provides a method for preparing the composition, comprising the steps of: mixing willow-leaf wintersweet powder with water, heating at 50-100°C for 0.5-3 hours, separating the solid and liquid, concentrating and drying the obtained liquid to obtain a willow-leaf wintersweet water extract, and mixing it with dipotassium glycyrrhizate to obtain the composition.

[0010] The above are conventional water extraction methods. The water extract of *Chimonanthus praecox* obtained by conventional water extraction methods can produce a synergistic effect with dipotassium glycyrrhizate to a certain extent.

[0011] Optionally, the mass-to-volume ratio of the willow-leaf wintersweet powder to water is 1 kg: 10~20 L.

[0012] Optionally, the particle size of the willow-leaf wintersweet powder is ≤200μm.

[0013] Optionally, the willow-leaf wintersweet powder is obtained by soaking, crushing and sieving the dried leaves and / or stems of willow-leaf wintersweet in liquid nitrogen.

[0014] Optionally, the solid-liquid separation method is centrifugation or gauze filtration.

[0015] Optionally, the concentration method is rotary evaporation, with a vacuum degree < -0.08 MPa and a temperature of 50~60℃, concentrating to 1 / 5~1 / 10 of the original volume.

[0016] Optionally, the drying method is freeze drying, the specific process of which includes: pre-freezing to -50~-40℃, and then sublimation drying under a vacuum of <10Pa for 36~48h.

[0017] Thirdly, the present invention provides a method for preparing the composition, comprising the steps of: S1: Mix willow-leaf wax plum powder with water, add phytic acid for multivalent cation solidification; S2: Place the product from S1 in a sealed container, evacuate it, and then fill it with CO2 for saturated permeation; S3: Add a nonionic surfactant to the product of S2 and homogenize it; S4: The product of S3 was subjected to flash evaporation and alternating dual-frequency ultrasonic extraction at 75~80℃. After solid-liquid separation, the obtained liquid was concentrated and dried to obtain the water extract of willow-leaf wax plum, which was then mixed with dipotassium glycyrrhizate to obtain the composition.

[0018] When the above-described preparation method of this invention is used, it is beneficial to selectively enrich the anti-inflammatory and soothing active ingredients in *Chimonanthus praecox*, enhance the anti-inflammatory and soothing efficacy of the water extract of *Chimonanthus praecox*, and improve its synergistic effect with dipotassium glycyrrhizate, for example: (1) In step S1, by adding phytic acid to perform polyvalent cation solidification, the Ca in the willow-leaf wintersweet can be chelated by phytic acid. 2+ and Mg 2+ This protects the effective concentration of dipotassium glycyrrhizate and prevents Ca2+ poisoning. 2+ and Mg 2+ It undergoes a metathesis reaction with dipotassium glycyrrhizate to form an insoluble precipitate, which leads to the salting out and deactivation of the latter.

[0019] (2) In step S3, a nonionic surfactant is added. On the one hand, it can improve the water extraction yield of hydrophobic anti-inflammatory flavonoids in *Chimonanthus praecox* through micellar solubilization during the extraction process. On the other hand, the nonionic surfactant is retained in the final product along with the extract. When it is compounded with dipotassium glycyrrhizate in the subsequent process, the two can self-assemble to form a thermodynamically more stable mixed micelle, reduce the critical micelle concentration of the system, further encapsulate and stabilize the hydrophobic anti-inflammatory flavonoids enriched by water extraction, and improve the solubility and stability of the formulation.

[0020] (3) In step S4, by controlling the temperature of flash evaporation and alternating dual-frequency ultrasonic extraction at 75-80℃, the phenolic hydroxyl conjugated double bonds of flavonoid glycosides can be preserved more completely, ensuring that they can accumulate with the pentacyclic triterpenoid skeleton of dipotassium glycyrrhizate after compounding. This conformational compatibility significantly enhances the capture affinity of the composition for HMGB1 factor, and through the synergy of upstream signal interception and downstream TRPV1 receptor regulation, a nonlinear leap in anti-inflammatory and soothing efficacy is achieved.

[0021] Experiments show that the composition prepared by the above method can effectively reduce the levels of IL-1β, TNF-α, IL-6 and IL-8, scavenge ROS, inhibit NO production, downregulate TRPV1 expression, and reduce mast cell degranulation rate, thereby achieving a good anti-inflammatory and soothing effect and effectively reducing skin hemoglobin content.

[0022] Optionally, in step S1, cellulase is added before, at the same time as, or after adding phytic acid; the amounts of phytic acid and cellulase are 0.15~0.25wt% and 0.4~0.6wt% of the willow-leaf wax plum powder, respectively.

[0023] Cellulase can not only promote the release of active ingredients by decomposing the cell walls of *Chimonanthus praecox*, but also promote the release of active ingredients under the action of CO2 by facilitating the penetration of CO2 into the powder of *Chimonanthus praecox* leaves.

[0024] Optionally, in step S3, the nonionic surfactant includes alkyl glycosides and / or polyglycerol fatty acid esters, and the amount used is 0.2~0.4wt% of the mass of the willow-leaf wax plum powder; the homogenization speed is 18000~20000rpm, the time is 10~15min, and the temperature of the liquid is ≤30℃ during the period.

[0025] Optionally, in step S2, the process of vacuuming followed by CO2 saturation permeation includes: vacuuming to -0.08 to -0.09 MPa, maintaining the pressure for 5 to 10 minutes, introducing CO2 to 1.2 to 1.5 MPa, and stirring at 35 to 40°C and 150 to 200 rpm for 30 to 60 minutes.

[0026] Optionally, in step S4, before performing the flash evaporation, the product S3 is preheated; the preheating and flash evaporation process includes: placing the product S3 in a sealed container, pressurizing it to 0.6~0.8MPa, heating it to 45~50℃, maintaining it for 5~10min, and then simultaneously depressurizing and heating, depressurizing it to atmospheric pressure at 0.2~0.3MPa / s, and heating it to 75~80℃ within 2.5~3.5min; the duration of the alternating dual-frequency ultrasonic extraction is 20~30min, the ultrasonic frequency is 25~30kHz and 40~45kHz, the ultrasonic frequency is switched every 3~5s, and the ultrasonic power is 550~650W.

[0027] Optionally, in step S1, the mass-to-volume ratio of the willow-leaf wax plum powder to water is 1 kg: 12~14 L.

[0028] Optionally, in step S1, the particle size of the willow-leaf wax plum powder is ≤200μm.

[0029] Optionally, in step S1, the willow-leaf wintersweet powder is obtained by soaking, crushing and sieving the dried leaves and / or stems of willow-leaf wintersweet in liquid nitrogen.

[0030] Optionally, in step S4, the solid-liquid separation method is centrifugation or gauze filtration.

[0031] Optionally, in step S4, the concentration method is rotary evaporation, with a vacuum degree < -0.08 MPa and a temperature of 50~60℃, concentrating to 1 / 5~1 / 10 of the original volume.

[0032] Optionally, in step S4, the drying method is freeze drying, and the specific process includes: pre-freezing to -50~-40℃, and then sublimation drying under a vacuum degree <10Pa for 36~48h.

[0033] Fourthly, the present invention provides the use of the said composition or the composition prepared according to the said preparation method in the preparation of anti-inflammatory and soothing skin preparations.

[0034] Optionally, the skin anti-inflammatory and soothing preparation is a cosmetic, wherein the content of the composition is 0.005~5wt%.

[0035] Optionally, the cosmetic product is a toner, lotion, serum, cream, face cream, eye cream, or facial mask.

[0036] Optionally, the skin anti-inflammatory and soothing agent is an agent for reducing the levels of IL-1β, TNF-α, IL-6 and IL-8, or an agent for clearing ROS, or an agent for inhibiting NO production, or an agent for downregulating TRPV1 expression, or an agent for reducing mast cell degranulation rate.

[0037] Compared with the prior art, the present invention has the following advantages: (1) In the composition of the present invention, the aqueous extract of wax plum and dipotassium glycyrrhizate can achieve target synergistic effect, forming a synergistic effect of "upstream blocking-midstream interception-downstream sedation", thereby improving the anti-inflammatory and soothing effect of the composition on the skin.

[0038] (2) In the preparation method of the composition of the present invention, the conventional water extraction method has been specially improved. Through the comprehensive design of external additives, process steps and process parameters, it is beneficial to selectively enrich the anti-inflammatory and soothing active ingredients in the willow-leaf wax plum, improve the anti-inflammatory and soothing effects of the willow-leaf wax plum water extract itself, and enhance the synergistic effect between it and dipotassium glycyrrhizate, thereby further improving the anti-inflammatory and soothing effect of the composition on the skin. Attached Figure Description

[0039] Figure 1 The results show the ROS clearance rate of each drug administration group in Test Example 2.

[0040] Figure 2 The results show the inhibition rate of inflammatory factors in each drug administration group in Test Example 2.

[0041] Figure 3 The results show the NO content detection results in the culture supernatant of each group in Test Example 2.

[0042] Figure 4 The results show the relative expression levels of TRPV1 in each group in Test Example 2.

[0043] Figure 5 The results of mast cell degranulation rate detection in each group in Test Example 2 are shown.

[0044] Figure 6 The image shows the VISIA-CR red region chromatograms of the subjects in Test Example 3 before and after using a cosmetic containing 0.2 wt% composition CM2-1. Detailed Implementation

[0045] The present invention will be further described below with reference to the accompanying drawings and embodiments.

[0046] First, the present invention relates to a skin anti-inflammatory and soothing composition comprising a water extract of *Chimonanthus praecox* and dipotassium glycyrrhizate in a mass ratio of 1 to 3:1; wherein the water extract of *Chimonanthus praecox* is extracted from the leaves and / or stems of *Chimonanthus praecox*.

[0047] Second, the present invention relates to a method for preparing the composition, the steps of which include: mixing willow-leaf wax plum powder with water, heating at 50~100℃ for 0.5~3h, separating the solid and liquid, concentrating and drying the obtained liquid to obtain willow-leaf wax plum water extract, and mixing it with dipotassium glycyrrhizate to obtain the composition.

[0048] In some specific embodiments, the mass-to-volume ratio of the willow-leaf wax plum powder to water is 1 kg: 10~20 L.

[0049] In some specific embodiments, the particle size of the willow-leaf wax plum powder is ≤200μm.

[0050] In some specific embodiments, the willow-leaf wintersweet powder is obtained by soaking dried leaves and / or stems of willow-leaf wintersweet in liquid nitrogen, pulverizing, and sieving. Optionally or preferably, the mass-to-volume ratio of the dried willow-leaf wintersweet leaves to liquid nitrogen is 1 kg: 5-8 L; the soaking time in liquid nitrogen is 15-20 min; the pulverizing process includes pulverizing at 23000-27000 rpm in a high-speed pulverizer for 1-3 min, repeated 2-3 times.

[0051] In some specific embodiments, the solid-liquid separation method is centrifugation or gauze filtration.

[0052] In some specific embodiments, the concentration method is rotary evaporation, with a vacuum degree < -0.08 MPa and a temperature of 50~60℃, concentrating to 1 / 5~1 / 10 of the original volume.

[0053] In some specific embodiments, the drying method is freeze drying, and the specific process includes: pre-freezing to -50~-40℃, and then sublimation drying under a vacuum degree <10Pa for 36~48h.

[0054] Third, the present invention relates to a method for preparing the composition, comprising the following steps: S1: Mix willow-leaf wax plum powder with water, add phytic acid for multivalent cation solidification; S2: Place the product from S1 in a sealed container, evacuate it, and then fill it with CO2 for saturated permeation; S3: Add a nonionic surfactant to the product of S2 and homogenize it; S4: The product of S3 was subjected to flash evaporation and alternating dual-frequency ultrasonic extraction at 75~80℃. After solid-liquid separation, the obtained liquid was concentrated and dried to obtain the water extract of willow-leaf wax plum, which was then mixed with dipotassium glycyrrhizate to obtain the composition.

[0055] In some specific embodiments, in step S1, the mass-to-volume ratio of the willow-leaf wax plum powder to water is 1 kg: 12~14 L.

[0056] In some specific embodiments, in step S1, the particle size of the willow-leaf wax plum powder is ≤200μm.

[0057] In some specific embodiments, in step S1, the willow-leaf wintersweet powder is obtained by soaking dried leaves and / or stems of willow-leaf wintersweet in liquid nitrogen, pulverizing, and sieving. Optionally or preferably, the mass-to-volume ratio of the dried willow-leaf wintersweet leaves to liquid nitrogen is 1 kg: 5-8 L; the soaking time in liquid nitrogen is 15-20 min; the pulverizing process includes pulverizing at 23000-27000 rpm in a high-speed pulverizer for 1-3 min, repeated 2-3 times.

[0058] In some specific embodiments, in step S1, the amount of phytic acid used is 0.15~0.25wt% of the willow-leaf wax plum powder.

[0059] In some specific embodiments, in step S1, cellulase is added before, at the same time as, or after adding phytic acid; the amount of cellulase is 0.4 to 0.6 wt% of the willow-leaf wax plum powder.

[0060] In some specific embodiments, step S2, the process of vacuuming followed by CO2 saturation permeation includes: vacuuming to -0.08 to -0.09 MPa, maintaining the pressure for 5 to 10 minutes, introducing CO2 to 1.2 to 1.5 MPa, and stirring at 35 to 40°C and 150 to 200 rpm for 30 to 60 minutes.

[0061] In some specific embodiments, in step S3, the nonionic surfactant includes alkyl glycosides and / or polyglycerol fatty acid esters, and the amount used is 0.2~0.4 wt% of the weight of the willow-leaf wax plum powder.

[0062] In some specific embodiments, in step S3, the rotation speed of the homogenization is 18000~20000 rpm, the time is 10~15 min, and the temperature of the liquid is ≤30℃ during the period.

[0063] In some specific embodiments, in step S4, before performing the flash evaporation, the product S3 is preheated; the preheating and flash evaporation process includes: placing the product S3 in a sealed container, pressurizing it to 0.6~0.8MPa, heating it to 45~50℃, maintaining it for 5~10min, and then simultaneously depressurizing and heating, depressurizing it to atmospheric pressure at 0.2~0.3MPa / s, and heating it to 75~80℃ within 2.5~3.5min.

[0064] In some specific embodiments, in step S4, the duration of the alternating dual-frequency ultrasound extraction is 20-30 minutes, the ultrasound frequency is 25-30 kHz and 40-45 kHz, the ultrasound frequency is switched every 3-5 seconds, and the ultrasound power is 550-650 W.

[0065] In some specific embodiments, in step S4, the solid-liquid separation method is centrifugation or gauze filtration.

[0066] In some specific embodiments, in step S4, the concentration method is rotary evaporation, with a vacuum degree < -0.08MPa and a temperature of 50~60℃, concentrating to 1 / 5~1 / 10 of the original volume.

[0067] In some specific embodiments, in step S4, the drying method is freeze drying, and the specific process includes: pre-freezing to -50~-40℃, and then sublimation drying under a vacuum degree <10Pa for 36~48h.

[0068] Fourth, the present invention relates to the use of the composition or the composition prepared according to the preparation method in the preparation of anti-inflammatory and soothing skin preparations.

[0069] Optionally, the skin anti-inflammatory and soothing preparation is a cosmetic, wherein the content of the composition is 0.005~5wt%.

[0070] Optionally, the cosmetic product is a toner, lotion, serum, cream, face cream, eye cream, or facial mask.

[0071] Optionally, the skin anti-inflammatory and soothing agent is an agent for reducing the levels of IL-1β, TNF-α, IL-6 and IL-8, or an agent for clearing ROS, or an agent for inhibiting NO production, or an agent for downregulating TRPV1 expression, or an agent for reducing mast cell degranulation rate.

[0072] The present invention will now be described with reference to specific embodiments and comparative examples. It should be understood that these embodiments are for illustrative purposes only and are not intended to limit the scope of the invention.

[0073] Preparation Example 1: Preparation of water extract CSE1 from willow-leaf wintersweet and anti-inflammatory and soothing skin composition CM1 In this preparation example, a water extract of *Chimonanthus praecox* was prepared using a conventional water extraction method, and then further formulated into a skin anti-inflammatory and soothing composition. Specifically, the preparation steps of the water extract of *Chimonanthus praecox* and the skin anti-inflammatory and soothing composition in this preparation example are as follows: S1: Preparation of willow-leaf wax plum powder S1.1: Place 1 kg of dried willow-leaf wintersweet leaves in a stainless steel freezing container, slowly pour in 7 L of liquid nitrogen to ensure complete immersion, and let stand for 18 minutes to allow the leaves to become brittle.

[0074] S1.2: After completing step S1.1, the leaves are transferred in batches into a high-speed pulverizer and pulverized at 25,000 rpm for 1 minute. This process is repeated 3 times and the leaves are passed through an 80-mesh sieve to obtain willow leaf wax plum powder.

[0075] S2: Water extraction Take 1 kg of the willow-leaf wax plum powder prepared according to step S1, add it to 20 L of deionized water, heat and reflux at 100℃ for 0.5 h, cool to room temperature, and obtain the extract.

[0076] S3: Solid-liquid separation and drying S3.1: Centrifuge the extract at 4000 rpm for 15 min and collect the supernatant.

[0077] S3.2: Transfer the supernatant into a rotary evaporator, maintain the vacuum degree below -0.08MPa, and the water bath temperature at 55℃, concentrate to 1 / 7 of the original volume to obtain an extract.

[0078] S3.3: Spread the extract in a freeze-drying pan, pre-freeze to -40°C, then maintain the vacuum degree below 10 Pa and sublimate dry for 48 hours to obtain the water extract of willow-leaf wintersweet (numbered "CSE1").

[0079] S4: Mixing Take the water extract CSE1 of willow-leaf wax plum prepared according to the method of this preparation example, mix it with dipotassium glycyrrhizate at a mass ratio of 2:1 at room temperature to obtain a skin anti-inflammatory and soothing composition (numbered "CM1").

[0080] Preparation Example 2: Preparation of water extract CSE2 from *Chimonanthus praecox* and anti-inflammatory and soothing skin compositions CM2-1~CM2-6 This preparation example uses the improved water extraction method of the present invention to prepare a water extract of *Chimonanthus praecox*, which is then further formulated into a skin anti-inflammatory and soothing composition. Specifically, the preparation steps of the water extract of *Chimonanthus praecox* and the skin anti-inflammatory and soothing composition in this preparation example are as follows: S1: Preparation of willow-leaf wax plum powder S1.1: Place 1 kg of dried willow-leaf wintersweet leaves in a stainless steel freezing container, slowly pour in 7 L of liquid nitrogen to ensure complete immersion, and let stand for 18 minutes to allow the leaves to become brittle.

[0081] S1.2: After completing step S1.1, the leaves are transferred in batches into a high-speed pulverizer and pulverized at 25,000 rpm for 1 minute. This process is repeated 3 times and the leaves are passed through an 80-mesh sieve to obtain willow leaf wax plum powder.

[0082] S2: Multivalent cation solidification and high-pressure synergistic enzymatic CO2 permeation S2.1: Take 1 kg of willow-leaf wax plum powder prepared according to step S1, add it to 13 L of deionized water, add 2 g of phytic acid and 5 g of acidic cellulase (purchased from Cangzhou Xiasheng Enzyme Biotechnology, brand name SPE-017 for plant extraction), stir at 200 rpm for 30 minutes at room temperature to obtain a mixture.

[0083] S2.2: Transfer the mixture into the reactor, seal it and evacuate it to -0.08MPa, and maintain the pressure for 8 minutes.

[0084] S2.3: Introduce CO2 into the reactor until the pressure inside the reactor reaches 1.3 MPa, and stir for 40 min at 38℃ and 200 rpm.

[0085] S3: Nonionic surfactant intervention and homogenization Add 3g of alkyl glycoside (APG) (purchased from Shanghai Youwen Chemical Co., Ltd., brand name Plantacare 1200UP) to the mixture after step S2 treatment, and continuously homogenize at 19000rpm for 15min, during which the temperature of the liquid is controlled not to exceed 30℃, to obtain a uniformly distributed suspension. At this time, CO2 still exists in a dissolved state in the liquid phase and inside the particles.

[0086] S4: Third-order gradient thermal extraction S4.1: Transfer the suspension obtained in step S3 into the extraction tank, adjust the pressure inside the tank to 0.7 MPa, raise the temperature to 48°C and maintain it for 5 min.

[0087] S4.2: Simultaneously begin depressurization and heating, rapidly depressurize to atmospheric pressure at a rate of 0.25 MPa / s, and heat to 78°C within 3 minutes.

[0088] S4.3: Maintain the temperature of the liquid at 78℃ and perform dual-frequency ultrasonic extraction at alternating ultrasonic frequencies of 28kHz and 40kHz for 20 minutes, switching the ultrasonic frequency every 4 seconds during the process. The ultrasonic power is 600W to obtain the extract.

[0089] S5: Solid-liquid separation and drying S5.1: Centrifuge the extract at 4000 rpm for 15 min and collect the supernatant.

[0090] S5.2: Transfer the supernatant into a rotary evaporator, maintain the vacuum degree below -0.08MPa, and the water bath temperature at 55℃, concentrate to 1 / 7 of the original volume to obtain an extract.

[0091] S5.3: Spread the extract in a freeze-drying pan, pre-freeze to -40°C, then maintain the vacuum degree below 10 Pa and sublimate dry for 48 hours to obtain the water extract of willow-leaf wintersweet (numbered "CSE2").

[0092] S6: Mixing Take the water extract CSE2 of willow-leaf wax plum prepared according to the method of this preparation example, and mix it with other components in accordance with the formula in Table 1 at room temperature to obtain various anti-inflammatory and soothing skin compositions.

[0093] Table 1 Formulations of skin anti-inflammatory and soothing compositions CM2-1~CM2-6

[0094] Preparation Example 3: Preparation of water extract CSE3 from willow-leaf wintersweet and anti-inflammatory and soothing skin composition CM3 This preparation example uses the improved water extraction method of the present invention to prepare a water extract of *Chimonanthus praecox*, which is then further formulated into a skin anti-inflammatory and soothing composition. Specifically, the preparation steps of the water extract of *Chimonanthus praecox* and the skin anti-inflammatory and soothing composition in this preparation example are as follows: S1: Preparation of willow-leaf wax plum powder S1.1: Place 1 kg of dried willow-leaf wintersweet leaves in a stainless steel freezing container, slowly pour in 7 L of liquid nitrogen to ensure complete immersion, and let stand for 18 minutes to allow the leaves to become brittle.

[0095] S1.2: After completing step S1.1, the leaves are transferred in batches into a high-speed pulverizer and pulverized at 25,000 rpm for 1 minute. This process is repeated 3 times and the leaves are passed through an 80-mesh sieve to obtain willow leaf wax plum powder.

[0096] S2: Multivalent cation solidification and high-pressure synergistic enzymatic CO2 permeation S2.1: Take 1 kg of willow-leaf wax plum powder prepared according to step S1, add it to 13 L of deionized water, add 1.5 g of phytic acid and 6 g of acidic cellulase (purchased from Cangzhou Xiasheng Enzyme Biotechnology, brand name SPE-017 for plant extraction), stir at 200 rpm for 30 minutes at room temperature to obtain a mixture.

[0097] S2.2: Transfer the mixture into the reactor, seal it and evacuate it to -0.08MPa, and maintain the pressure for 10 minutes.

[0098] S2.3: Introduce CO2 into the reactor until the pressure inside the reactor reaches 1.2 MPa, and stir for 60 min at 35℃ and 200 rpm.

[0099] S3: Nonionic surfactant intervention and homogenization Add 2g of alkyl glycoside (APG) (purchased from Shanghai Youwen Chemical Co., Ltd., brand name Plantacare 1200UP) to the mixture after step S2 treatment, and continuously homogenize at 18000rpm for 15min, during which the temperature of the liquid is controlled not to exceed 30℃, to obtain a uniformly distributed suspension. At this time, CO2 still exists in a dissolved state in the liquid phase and inside the particles.

[0100] S4: Third-order gradient thermal extraction S4.1: Transfer the suspension obtained in step S3 into the extraction tank, adjust the pressure inside the tank to 0.8 MPa, raise the temperature to 50°C and maintain it for 5 min.

[0101] S4.2: Simultaneously begin depressurization and heating, rapidly depressurize to atmospheric pressure at a rate of 0.3 MPa / s, and heat to 80°C within 3.5 minutes.

[0102] S4.3: Maintain the temperature of the liquid at 80℃ and perform dual-frequency ultrasonic extraction at alternating ultrasonic frequencies of 30kHz and 45kHz for 20 minutes, switching the ultrasonic frequency every 3 seconds during the process. The ultrasonic power is 650W to obtain the extract.

[0103] S5: Solid-liquid separation and drying S5.1: Centrifuge the extract at 4000 rpm for 15 min and collect the supernatant.

[0104] S5.2: Transfer the supernatant into a rotary evaporator, maintain the vacuum degree below -0.08MPa, and the water bath temperature at 55℃, concentrate to 1 / 7 of the original volume to obtain an extract.

[0105] S5.3: Spread the extract in a freeze-drying pan, pre-freeze to -40°C, then maintain the vacuum degree below 10 Pa and sublimate dry for 48 hours to obtain the water extract of willow-leaf wintersweet (numbered "CSE3").

[0106] S6: Mixing The aqueous extract CSE3 of *Chimonanthus praecox* prepared according to the method of this preparation example was mixed with dipotassium glycyrrhizate at a mass ratio of 2:1 at room temperature to obtain a skin anti-inflammatory and soothing composition (numbered "CM3").

[0107] Preparation Example 4: Preparation of water extract CSE4 from *Chimonanthus praecox* and skin anti-inflammatory and soothing composition CM4 This preparation example uses the improved water extraction method of the present invention to prepare a water extract of *Chimonanthus praecox*, which is then further formulated into a skin anti-inflammatory and soothing composition. Specifically, the preparation steps of the water extract of *Chimonanthus praecox* and the skin anti-inflammatory and soothing composition in this preparation example are as follows: S1: Preparation of willow-leaf wax plum powder S1.1: Place 1 kg of dried willow-leaf wintersweet leaves in a stainless steel freezing container, slowly pour in 7 L of liquid nitrogen to ensure complete immersion, and let stand for 18 minutes to allow the leaves to become brittle.

[0108] S1.2: After completing step S1.1, the leaves are transferred in batches into a high-speed pulverizer and pulverized at 25,000 rpm for 1 minute. This process is repeated 3 times and the leaves are passed through an 80-mesh sieve to obtain willow leaf wax plum powder.

[0109] S2: Multivalent cation solidification and high-pressure synergistic enzymatic CO2 permeation S2.1: Take 1 kg of willow-leaf wax plum powder prepared according to step S1, add it to 13 L of deionized water, add 2.5 g of phytic acid and 4 g of acidic cellulase (purchased from Cangzhou Xiasheng Enzyme Biotechnology, brand name SPE-017 for plant extraction), stir at 200 rpm for 30 minutes at room temperature to obtain a mixture.

[0110] S2.2: Transfer the mixture into the reactor, seal it and evacuate it to -0.09MPa, and maintain the pressure for 5 minutes.

[0111] S2.3: Introduce CO2 into the reactor until the pressure inside the reactor reaches 1.5 MPa, and stir for 30 min at 40℃ and 150 rpm.

[0112] S3: Nonionic surfactant intervention and homogenization Add 4g of polyglycerol fatty acid ester (purchased from Chengdu Maohesheng Technology) to the mixture after step S2, and continuously homogenize it at 20000rpm for 10min, during which the temperature of the liquid is controlled not to exceed 30℃, to obtain a uniformly distributed suspension. At this time, CO2 still exists in a dissolved state in the liquid phase and inside the particles.

[0113] S4: Third-order gradient thermal extraction S4.1: Transfer the suspension obtained in step S3 into the extraction tank, adjust the pressure inside the tank to 0.6 MPa, raise the temperature to 45°C and maintain it for 10 min.

[0114] S4.2: Simultaneously begin depressurization and heating, rapidly depressurize to atmospheric pressure at a rate of 0.2 MPa / s, and heat to 75°C within 2.5 minutes.

[0115] S4.3: Maintain the temperature of the liquid at 75℃ and perform dual-frequency ultrasonic extraction at alternating ultrasonic frequencies of 25kHz and 40kHz for 30 minutes, switching the ultrasonic frequency every 5 seconds during the process. The ultrasonic power is 550W to obtain the extract.

[0116] S5: Solid-liquid separation and drying S5.1: Centrifuge the extract at 4000 rpm for 15 min and collect the supernatant.

[0117] S5.2: Transfer the supernatant into a rotary evaporator, maintain the vacuum degree below -0.08MPa, and the water bath temperature at 55℃, concentrate to 1 / 7 of the original volume to obtain an extract.

[0118] S5.3: Spread the extract in a freeze-drying pan, pre-freeze to -40°C, then maintain the vacuum degree below 10 Pa and sublimate dry for 48 hours to obtain the water extract of willow-leaf wintersweet (numbered "CSE4").

[0119] S6: Mixing The aqueous extract of *Chimonanthus praecox* CSE4 prepared according to the method of this preparation example was mixed with dipotassium glycyrrhizate at a mass ratio of 2:1 at room temperature to obtain a skin anti-inflammatory and soothing composition (numbered "CM4").

[0120] Preparation Example 5: Preparation of water extract CSE5 from *Chimonanthus praecox* and skin anti-inflammatory and soothing composition CM5 The only difference between this preparation example and Preparation Example 4 is that phytic acid was not added for polyvalent cation solidification during the preparation of the water extract of *Chimonanthus praecox*; all other raw materials and steps are the same as in Preparation Example 4. Specifically, the preparation steps of the water extract of *Chimonanthus praecox* and the anti-inflammatory and soothing skin composition in this preparation example are as follows: S1: Preparation of willow-leaf wax plum powder S1.1: Place 1 kg of dried willow-leaf wintersweet leaves in a stainless steel freezing container, slowly pour in 7 L of liquid nitrogen to ensure complete immersion, and let stand for 18 minutes to allow the leaves to become brittle.

[0121] S1.2: After completing step S1.1, the leaves are transferred in batches into a high-speed pulverizer and pulverized at 25,000 rpm for 1 minute. This process is repeated 3 times and the leaves are passed through an 80-mesh sieve to obtain willow leaf wax plum powder.

[0122] S2: High-pressure synergistic enzymatic CO2 osmosis S2.1: Take 1 kg of willow-leaf wax plum powder prepared according to step S1, add it to 13 L of deionized water, add 4 g of acidic cellulase (purchased from Cangzhou Xiasheng Enzyme Biotechnology, brand name SPE-017 for plant extraction), stir at 200 rpm for 30 minutes at room temperature to obtain a mixture.

[0123] S2.2: Transfer the mixture into the reactor, seal it and evacuate it to -0.09MPa, and maintain the pressure for 5 minutes.

[0124] S2.3: Introduce CO2 into the reactor until the pressure inside the reactor reaches 1.5 MPa, and stir for 30 min at 40℃ and 150 rpm.

[0125] S3: Nonionic surfactant intervention and homogenization Add 4g of polyglycerol fatty acid ester (purchased from Chengdu Maohesheng Technology) to the mixture after step S2, and continuously homogenize it at 20000rpm for 10min, during which the temperature of the liquid is controlled not to exceed 30℃, to obtain a uniformly distributed suspension. At this time, CO2 still exists in a dissolved state in the liquid phase and inside the particles.

[0126] S4: Third-order gradient thermal extraction S4.1: Transfer the suspension obtained in step S3 into the extraction tank, adjust the pressure inside the tank to 0.6 MPa, raise the temperature to 45°C and maintain it for 10 min.

[0127] S4.2: Simultaneously begin depressurization and heating, rapidly depressurize to atmospheric pressure at a rate of 0.2 MPa / s, and heat to 75°C within 2.5 minutes.

[0128] S4.3: Maintain the temperature of the liquid at 75℃ and perform dual-frequency ultrasonic extraction at alternating ultrasonic frequencies of 25kHz and 40kHz for 30 minutes, switching the ultrasonic frequency every 5 seconds during the process. The ultrasonic power is 550W to obtain the extract.

[0129] S5: Solid-liquid separation and drying S5.1: Centrifuge the extract at 4000 rpm for 15 min and collect the supernatant.

[0130] S5.2: Transfer the supernatant into a rotary evaporator, maintain the vacuum degree below -0.08MPa, and the water bath temperature at 55℃, concentrate to 1 / 7 of the original volume to obtain an extract.

[0131] S5.3: Spread the extract in a freeze-drying pan, pre-freeze to -40°C, then maintain the vacuum degree below 10 Pa and sublimate dry for 48 hours to obtain the water extract of willow-leaf wintersweet (numbered "CSE5").

[0132] S6: Mixing Take the water extract CSE5 of *Chimonanthus praecox* prepared according to the method of this preparation example, mix it with dipotassium glycyrrhizate at a mass ratio of 2:1 at room temperature to obtain a skin anti-inflammatory and soothing composition (numbered "CM5").

[0133] Preparation Example 6: Preparation of water extract CSE6 from *Chimonanthus praecox* and skin anti-inflammatory and soothing composition CM6 The only difference between this preparation example and Preparation Example 4 is that no nonionic surfactant (polyglycerol fatty acid ester) was added during the preparation of the water extract of *Chimonanthus praecox*. All other raw materials and steps are the same as in Preparation Example 4. Specifically, the preparation steps of the water extract of *Chimonanthus praecox* and the anti-inflammatory and soothing skin composition in this preparation example are as follows: S1: Preparation of willow-leaf wax plum powder S1.1: Place 1 kg of dried willow-leaf wintersweet leaves in a stainless steel freezing container, slowly pour in 7 L of liquid nitrogen to ensure complete immersion, and let stand for 18 minutes to allow the leaves to become brittle.

[0134] S1.2: After completing step S1.1, the leaves are transferred in batches into a high-speed pulverizer and pulverized at 25,000 rpm for 1 minute. This process is repeated 3 times and the leaves are passed through an 80-mesh sieve to obtain willow leaf wax plum powder.

[0135] S2: Multivalent cation solidification and high-pressure synergistic enzymatic CO2 permeation S2.1: Take 1 kg of willow-leaf wax plum powder prepared according to step S1, add it to 13 L of deionized water, add 2.5 g of phytic acid and 4 g of acidic cellulase (purchased from Cangzhou Xiasheng Enzyme Biotechnology, brand name SPE-017 for plant extraction), stir at 200 rpm for 30 minutes at room temperature to obtain a mixture.

[0136] S2.2: Transfer the mixture into the reactor, seal it and evacuate it to -0.09MPa, and maintain the pressure for 5 minutes.

[0137] S2.3: Introduce CO2 into the reactor until the pressure inside the reactor reaches 1.5 MPa, and stir for 30 min at 40℃ and 150 rpm.

[0138] S3: Homogeneous After completing step S2, the mixture is continuously homogenized at 20,000 rpm for 10 minutes, during which the temperature of the liquid is controlled not to exceed 30°C, to obtain a uniformly distributed suspension. At this time, CO2 still exists in a dissolved state in the liquid phase and inside the particles.

[0139] S4: Third-order gradient thermal extraction S4.1: Transfer the suspension obtained in step S3 into the extraction tank, adjust the pressure inside the tank to 0.6 MPa, raise the temperature to 45°C and maintain it for 10 min.

[0140] S4.2: Simultaneously begin depressurization and heating, rapidly depressurize to atmospheric pressure at a rate of 0.2 MPa / s, and heat to 75°C within 2.5 minutes.

[0141] S4.3: Maintain the temperature of the liquid at 75℃ and perform dual-frequency ultrasonic extraction at alternating ultrasonic frequencies of 25kHz and 40kHz for 30 minutes, switching the ultrasonic frequency every 5 seconds during the process. The ultrasonic power is 550W to obtain the extract.

[0142] S5: Solid-liquid separation and drying S5.1: Centrifuge the extract at 4000 rpm for 15 min and collect the supernatant.

[0143] S5.2: Transfer the supernatant into a rotary evaporator, maintain the vacuum degree below -0.08MPa, and the water bath temperature at 55℃, concentrate to 1 / 7 of the original volume to obtain an extract.

[0144] S5.3: Spread the extract in a freeze-drying pan, pre-freeze to -40°C, then maintain the vacuum degree below 10 Pa and sublimate dry for 48 hours to obtain the water extract of willow-leaf wintersweet (numbered "CSE6").

[0145] S6: Mixing The aqueous extract of *Chimonanthus praecox* CSE6 prepared according to the method of this preparation example was mixed with dipotassium glycyrrhizate at a mass ratio of 2:1 at room temperature to obtain a skin anti-inflammatory and soothing composition (numbered "CM6").

[0146] Preparation Example 7: Preparation of water extract CSE7 from *Chimonanthus praecox* and skin anti-inflammatory and soothing composition CM7 The only difference between this preparation example and Preparation Example 4 is that the temperature during flash evaporation and alternating dual-frequency ultrasonic extraction was increased in the preparation of the water extract of *Chimonanthus praecox*. All other raw materials and steps are the same as in Preparation Example 4. Specifically, the preparation steps of the water extract of *Chimonanthus praecox* and the anti-inflammatory and soothing skin composition in this preparation example are as follows: S1: Preparation of willow-leaf wax plum powder S1.1: Place 1 kg of dried willow-leaf wintersweet leaves in a stainless steel freezing container, slowly pour in 7 L of liquid nitrogen to ensure complete immersion, and let stand for 18 minutes to allow the leaves to become brittle.

[0147] S1.2: After completing step S1.1, the leaves are transferred in batches into a high-speed pulverizer and pulverized at 25,000 rpm for 1 minute. This process is repeated 3 times and the leaves are passed through an 80-mesh sieve to obtain willow leaf wax plum powder.

[0148] S2: Multivalent cation solidification and high-pressure synergistic enzymatic CO2 permeation S2.1: Take 1 kg of willow-leaf wax plum powder prepared according to step S1, add it to 13 L of deionized water, add 2.5 g of phytic acid and 4 g of acidic cellulase (purchased from Cangzhou Xiasheng Enzyme Biotechnology, brand name SPE-017 for plant extraction), stir at 200 rpm for 30 minutes at room temperature to obtain a mixture.

[0149] S2.2: Transfer the mixture into the reactor, seal it and evacuate it to -0.09MPa, and maintain the pressure for 5 minutes.

[0150] S2.3: Introduce CO2 into the reactor until the pressure inside the reactor reaches 1.5 MPa, and stir for 30 min at 40℃ and 150 rpm.

[0151] S3: Nonionic surfactant intervention and homogenization Add 4g of polyglycerol fatty acid ester (purchased from Chengdu Maohesheng Technology) to the mixture after step S2, and continuously homogenize it at 20000rpm for 10min, during which the temperature of the liquid is controlled not to exceed 30℃, to obtain a uniformly distributed suspension. At this time, CO2 still exists in a dissolved state in the liquid phase and inside the particles.

[0152] S4: Third-order gradient thermal extraction S4.1: Transfer the suspension obtained in step S3 into the extraction tank, adjust the pressure inside the tank to 0.6 MPa, raise the temperature to 45°C and maintain it for 10 min.

[0153] S4.2: Simultaneously begin depressurization and heating, rapidly depressurize to atmospheric pressure at a rate of 0.2 MPa / s, and heat to 85°C within 2.5 minutes.

[0154] S4.3: Maintain the temperature of the liquid at 85℃ and perform dual-frequency ultrasonic extraction at alternating ultrasonic frequencies of 25kHz and 40kHz for 30 minutes, switching the ultrasonic frequency every 5 seconds during the process. The ultrasonic power is 550W to obtain the extract.

[0155] S5: Solid-liquid separation and drying S5.1: Centrifuge the extract at 4000 rpm for 15 min and collect the supernatant.

[0156] S5.2: Transfer the supernatant into a rotary evaporator, maintain the vacuum degree below -0.08MPa, and the water bath temperature at 55℃, concentrate to 1 / 7 of the original volume to obtain an extract.

[0157] S5.3: Spread the extract in a freeze-drying pan, pre-freeze to -40°C, then maintain the vacuum degree below 10 Pa and sublimate dry for 48 hours to obtain the water extract of willow-leaf wintersweet (numbered "CSE7").

[0158] S6: Mixing The aqueous extract of *Chimonanthus praecox* CSE7 prepared according to the method of this preparation example was mixed with dipotassium glycyrrhizate at a mass ratio of 2:1 at room temperature to obtain a skin anti-inflammatory and soothing composition (numbered "CM7").

[0159] Preparation Example 8: Preparation of water extract CSE8 from *Chimonanthus praecox* and anti-inflammatory and soothing skin composition CM8 The only difference between this preparation example and Preparation Example 4 is that, in the preparation of the water extract of *Chimonanthus praecox*, phytic acid is added after high-pressure synergistic enzymatic CO2 permeation; all other raw materials and steps are the same as in Preparation Example 4. Specifically, the preparation steps of the water extract of *Chimonanthus praecox* and the anti-inflammatory and soothing skin composition in this preparation example are as follows: S1: Preparation of willow-leaf wax plum powder S1.1: Place 1 kg of dried willow-leaf wintersweet leaves in a stainless steel freezing container, slowly pour in 7 L of liquid nitrogen to ensure complete immersion, and let stand for 18 minutes to allow the leaves to become brittle.

[0160] S1.2: After completing step S1.1, the leaves are transferred in batches into a high-speed pulverizer and pulverized at 25,000 rpm for 1 minute. This process is repeated 3 times and the leaves are passed through an 80-mesh sieve to obtain willow leaf wax plum powder.

[0161] S2: High-pressure synergistic enzymatic CO2 osmosis S2.1: Take 1 kg of willow-leaf wax plum powder prepared according to step S1, add it to 13 L of deionized water, add 4 g of acidic cellulase (purchased from Cangzhou Xiasheng Enzyme Biotechnology, brand name SPE-017 for plant extraction), stir at 200 rpm for 30 minutes at room temperature to obtain a mixture.

[0162] S2.2: Transfer the mixture into the reactor, seal it and evacuate it to -0.09MPa, and maintain the pressure for 5 minutes.

[0163] S2.3: Introduce CO2 into the reactor until the pressure inside the reactor reaches 1.5 MPa, and stir for 30 min at 40℃ and 150 rpm.

[0164] S3: Multivalent cation solidification, nonionic surfactant intervention, and homogenization Add 2.5g of phytic acid and 4g of polyglycerol fatty acid ester (purchased from Chengdu Maohesheng Technology) to the mixture after step S2 treatment, and continuously homogenize at 20000rpm for 10min, during which the temperature of the liquid is controlled not to exceed 30℃, to obtain a uniformly distributed suspension. At this time, CO2 still exists in a dissolved state in the liquid phase and inside the particles.

[0165] S4: Third-order gradient thermal extraction S4.1: Transfer the suspension obtained in step S3 into the extraction tank, adjust the pressure inside the tank to 0.6 MPa, raise the temperature to 45°C and maintain it for 10 min.

[0166] S4.2: Simultaneously begin depressurization and heating, rapidly depressurize to atmospheric pressure at a rate of 0.2 MPa / s, and heat to 75°C within 2.5 minutes.

[0167] S4.3: Maintain the temperature of the liquid at 75℃ and perform dual-frequency ultrasonic extraction at alternating ultrasonic frequencies of 25kHz and 40kHz for 30 minutes, switching the ultrasonic frequency every 5 seconds during the process. The ultrasonic power is 550W to obtain the extract.

[0168] S5: Solid-liquid separation and drying S5.1: Centrifuge the extract at 4000 rpm for 15 min and collect the supernatant.

[0169] S5.2: Transfer the supernatant into a rotary evaporator, maintain the vacuum degree below -0.08MPa, and the water bath temperature at 55℃, concentrate to 1 / 7 of the original volume to obtain an extract.

[0170] S5.3: Spread the extract in a freeze-drying pan, pre-freeze to -40°C, then maintain the vacuum degree below 10 Pa and sublimate dry for 48 hours to obtain the water extract of willow-leaf wintersweet (numbered "CSE8").

[0171] S6: Mixing Take the water extract CSE8 of *Chimonanthus praecox* prepared according to the method of this preparation example, mix it with dipotassium glycyrrhizate at a mass ratio of 2:1 at room temperature to obtain a skin anti-inflammatory and soothing composition (numbered "CM8").

[0172] Test Example 1: Yield of water extract of *Chimonanthus praecox* leaves In the process of preparing the aqueous extract of *Chimonanthus praecox* in each preparation example, the yield of the aqueous extract was calculated, and the results are shown in Table 2.

[0173] Table 2 Effect of different extraction methods on yield

[0174] Test Example 2: In vitro experiment on anti-inflammatory and soothing effects The in vitro experiments aimed to systematically evaluate the synergistic effect of the combination of water extract of *Chimonanthus praecox* and dipotassium glycyrrhizate on anti-inflammatory, soothing, and neurosensory modulation of the skin. The experiment established in vitro cell models induced by lipopolysaccharide (LPS) or degranulation stimulants (Compound 48 / 80). First, the ability of the composition to inhibit early oxidative damage and prevent inflammation initiation was assessed by detecting the clearance rate of reactive oxygen species (ROS). Based on this, the secretion levels of key midstream pro-inflammatory cytokines (IL-1, TNF-alpha, IL-6, and IL-8) were quantitatively measured to demonstrate the composition's blocking effect on the inflammatory cascade and its multi-target synergistic antagonistic ability. Simultaneously, the physiological efficacy in inhibiting capillary dilation and improving skin redness was evaluated by monitoring nitric oxide (NO) release. Finally, by examining changes in TRPV1 ion channel activity and histamine release, the composition's terminal soothing effects in relieving itching, allergies, and skin discomfort were verified from two dimensions: regulation of the nerve receptive field and inhibition of allergic mediators. This demonstrates the synergistic effect of the water extract of *Chimonanthus praecox* and dipotassium glycyrrhizate.

[0175] 2.1 Experimental Group Design (1) Blank control group: cells cultured normally, without the use of inducing agents or drugs.

[0176] (2) Model group: Only the inducer was used, without administration of drugs.

[0177] (3) Set up the following 8 drug administration groups: Single component group A: Using an inducer and administering water extract of *Chimonanthus praecox* CSE2 (0.1 wt% added to the culture medium); Single-component group B: Using an inducer and administering dipotassium glycyrrhizate (0.1 wt% added to the culture medium). CM2-1 group: Inducer was used, and the skin anti-inflammatory and soothing composition CM2-1 (added at 0.1 wt% in the culture medium) was administered. CM2-2 group: Inducer was used, and the skin anti-inflammatory and soothing composition CM2-2 (added at 0.1 wt% in the culture medium) was administered. CM2-3 group: Inducer was used, and the skin anti-inflammatory and soothing composition CM2-3 (added at 0.1 wt% in the culture medium) was administered. CM2-4 group: Inducer was used, and the skin anti-inflammatory and soothing composition CM2-4 (added at 0.1 wt% in the culture medium) was administered. CM2-5 group: Inducer was used, and the skin anti-inflammatory and soothing composition CM2-5 (added at 0.1 wt% in the culture medium) was administered. CM2-6 group: The skin anti-inflammatory and soothing composition CM2-6 (added at 0.1 wt% in the culture medium) was administered using an inducer.

[0178] 2.2 General Preprocessing The following steps are general procedures before performing IL-1β, TNF-α, IL-6, IL-8, NO, ROS, histamine, and TRPV1 assays: (1) Cell line selection: For the detection of IL-1β, TNF-α, IL-6, IL-8, NO and ROS: RAW264.7 mouse macrophages.

[0179] For histamine detection: RBL-2H3 rat basophilic leukemia cells (mast cell model).

[0180] For TRPV1 detection: HaCaT human keratinocytes.

[0181] (2) Cell culture: The culture was carried out in DMEM high-glucose medium containing 10% fetal bovine serum (FBS) at 37°C and 5% CO2.

[0182] (3) Security screening (MTT method): To ensure that the experimental results were not caused by cytotoxicity, a concentration gradient test was first performed on each drug administration group. The highest concentration with cell viability greater than 90% was selected as the maximum dosage for subsequent experiments, i.e., the dosage was 0.1 wt%.

[0183] (4) Cell seeding: Cells were loaded at a rate of 1×10 5 The density of cells per well was seeded in 96-well plates.

[0184] (5) Drug administration: Once the cells have adhered to the culture medium and reached 80% confluence, discard the original culture medium and pretreat them for 2 hours with maintenance culture medium containing the corresponding test substance, according to the drug administration regimen of each group.

[0185] (6) Inducing stimulus: For the detection of IL-1β, TNF-α, IL-6, IL-8, NO, ROS and TRPV1: Add 1 μg / mL of LPS (lipopolysaccharide) as an inducer and continue incubation for 24 hours.

[0186] For histamine detection: Add 10 μg / mL of Compound 48 / 80 (degranulation stimulant) as an inducer and induce for 30 minutes.

[0187] 2.3 Detection Methods 2.3.1 ELISA sandwich assay (detection of IL-1β, TNF-α, IL-6, IL-8 and histamine) Supernatant collection: Collect the cell culture supernatant from each group, centrifuge at 3000 rpm for 10 minutes at 4℃, and collect the supernatant.

[0188] Sample addition and incubation: Following the ELISA kit instructions, add the standard and supernatant samples to the microplate and incubate with biotinylated antibody.

[0189] Color development and reading: After adding HRP-labeled avidin and washing the plate, add TMB substrate. Finally, add stop solution and measure the OD value at 450 nm using a microplate reader.

[0190] Concentration calculation: Calculate the secretion level of each group of factors based on the standard curve (the result is denoted as "C"). Then, calculate the inflammatory factor inhibition rate (%) = (C...). 模型组 -C 给药组 ) / (C 模型组 -C 空白对照组 The inhibition rate of inflammatory factors in each treatment group was calculated by multiplying the result by 100%.

[0191] 2.3.2 Gliese's reagent method (NO detection) Take 50 μL of culture supernatant and add an equal volume of Griess Reagent I and II. Incubate in the dark for 10 minutes, then measure the absorbance at 540 nm. Calculate the content of each group according to the sodium nitrite standard curve (the result is denoted as "C"). Then, calculate the NO inhibition rate (%) using the formula: (C = ... 模型组 -C 给药组 ) / (C 模型组 -C 空白对照组 The NO inhibition rate of each drug administration group was calculated by multiplying the result by 100%.

[0192] 2.3.3 DCFH-DA probe method (ROS detection) Remove the culture medium, add DCFH-DA working solution to a final concentration of 10 μmol / L, incubate at 37°C for 20 minutes, wash cells three times with serum-free culture medium to remove probes that have not entered the cells, and then detect fluorescence intensity using a multi-functional microplate reader (excitation wavelength 488 nm, emission wavelength 525 nm) (the result is recorded as "FI"). The ROS clearance rate (%) is calculated as follows: (FI = ... 模型组 -FI 给药组 ) / (FI 模型组 -FI 空白对照组 The ROS clearance rate of each drug administration group was calculated by multiplying the ROS clearance rate by 100%.

[0193] 2.3.4 qRT-PCR method (detection of expression level of cell membrane protein TRPV1) RNA extraction: Total RNA was extracted from cells in each group using TRIzol reagent.

[0194] Reverse transcription: RNA was reverse transcribed into cDNA according to the instructions of the reverse transcription kit.

[0195] Real-time quantitative PCR: Amplification was performed using the SYBR Green method. GAPDH was used as an internal reference gene. TRPV1 gene expression level was detected.

[0196] Data analysis: using 2 -ΔΔCt The relative expression level was calculated using a method, and the results are expressed as relative mRNA levels.

[0197] 2.4 Test Results 2.4.1 Source Defense and Antioxidant: ROS Scavenging Capacity Analysis Reactive oxygen species (ROS) are among the earliest key signaling molecules produced during inflammation. Excessive ROS can not only directly cause oxidative damage to cells, but also further activate inflammatory signaling pathways such as NF-κB and MAPK, inducing the release of pro-inflammatory factors and thus initiating an inflammatory cascade. Therefore, inhibiting excessive ROS accumulation is an important prerequisite for achieving skin soothing and anti-inflammatory effects.

[0198] The intervention effect of the composition on the inflammation initiation phase was evaluated by detecting the ROS level induced by LPS. The results are shown in [Table / Reference]. Figure 1 ( Figure 1 In the text, "**" indicates p < 0.01.

[0199] Figure 1The results showed that LPS stimulation significantly increased intracellular ROS levels. All samples exhibited some ROS scavenging ability, but the compositions of this invention (CM2-1, CM2-2, and CM2-3) showed superior antioxidant activity. Specifically, the ROS scavenging rates of CM2-1, CM2-2, and CM2-3 reached 87.95%, 82.95%, and 79.07%, respectively, significantly higher than that of single-component group A (72.72%) and single-component group B (74.28%), and also superior to CM2-6 constructed by replacing dipotassium glycyrrhizate with asiaticoside. These results indicate that, under certain ratios, the aqueous extract of *Chimonanthus praecox* and dipotassium glycyrrhizate can synergistically scavenge ROS generated in the early stages of inflammation, inhibiting oxidative stress at its source and providing a basis for blocking subsequent inflammatory cascade reactions.

[0200] 2.4.2 Blocking of the inflammatory cascade: Analysis of inhibition of multi-target pro-inflammatory factors After inflammation is initiated, a large number of pro-inflammatory cytokines are continuously released. Among them, TNF-α, IL-1β, IL-6, and IL-8 are important inflammatory mediators that mediate the spread of inflammation, amplification of inflammation, and tissue damage, and their expression levels can directly reflect the severity of the inflammatory response.

[0201] The ability of the composition to intercept inflammatory signal transduction was verified by monitoring the expression of key midstream inflammatory factors. Results are shown in […]. Figure 2 .

[0202] Figure 2 The results show that the compositions of this invention (CM2-1, CM2-2, and CM2-3) exhibit significant inhibitory effects on multiple key pro-inflammatory factors, and the aqueous extract of *Chimonanthus praecox* and dipotassium glycyrrhizate can achieve effective synergy. Taking CM2-1 as an example, its inhibition rates against TNF-α, IL-1β, IL-6, and IL-8 reached 71.94%, 72.35%, 74.52%, and 71.10%, respectively; CM2-2 and CM2-3 also maintained high inhibitory levels. In contrast, the inhibition rates of single-component groups A and B were mostly in the range of 45%–56%. Although compositions CM2-4, CM2-5, and CM2-6 have certain activity, their overall effects are still significantly lower than those of the compositions of this invention. It is noteworthy that the compositions of this invention exhibit simultaneous inhibitory effects on all four inflammatory pathways—TNF-α, IL-1β, IL-6, and IL-8—rather than targeting only a single inflammatory factor, indicating that they can synergistically regulate the inflammatory network from multiple inflammatory signaling nodes, effectively blocking the inflammatory cascade amplification process. The ROS experimental results further demonstrate that the composition of the present invention can not only inhibit the oxidative stress response at the source of inflammation, but also further inhibit the transmission of inflammatory signals and the release of inflammatory mediators, thereby achieving continuous intervention on the entire inflammatory process.

[0203] 2.4.3 Improvement in downstream physiological manifestations: Evaluation of redness reduction, itch relief, and anti-allergic soothing effects. To further evaluate the ameliorative effect of the composition of this invention on skin sensitivity-related terminal manifestations, a comprehensive evaluation was conducted from three dimensions: inflammatory vasodilation, neurosensitivity regulation, and release of allergic mediators. This included NO release detection, TRPV1 expression detection, and mast cell degranulation rate detection. The results are shown below. Figures 3-5 ( Figures 3-5 In the diagram, "***" indicates p < 0.0005, and "****" indicates p < 0.0001. The experimental results are analyzed below: (1) NO release inhibition effect: Nitric oxide (NO) is an important vasoactive factor in inflammatory states. Its excessive release can lead to capillary dilation, increased local blood flow, and skin redness. Therefore, it is widely used to evaluate the redness-reducing ability of products.

[0204] Figure 3 The results showed that the NO release in the model group reached 5.63 μmol / L, significantly higher than the normal level. After treatment of each sample, the NO release decreased, with the compositions of this invention (CM2-1, CM2-2, and CM2-3) exhibiting the most significant inhibitory effect. The NO release in the CM2-1, CM2-2, and CM2-3 groups decreased to 3.25 μmol / L, 3.50 μmol / L, and 3.60 μmol / L, respectively, significantly lower than that of the single-component group A (4.44 μmol / L) and the single-component group B (4.29 μmol / L), and also superior to that of the CM2-4, CM2-5, and CM2-6 groups. These results indicate that, under certain ratios, the aqueous extract of *Chimonanthus praecox* and dipotassium glycyrrhizate can synergistically inhibit inflammation-induced excessive NO release, thereby reducing vasodilation and improving skin erythema and redness.

[0205] (2) Regulation effect of TRPV1 expression: TRPV1 is an important neurosensitive receptor closely related to burning, stinging, and neurogenic itching of the skin. Increased expression of TRPV1 usually indicates that neurogenic inflammation is activated.

[0206] Figure 4The results showed that the relative expression level of TRPV1 in the model group increased from 1.05 in the blank control group to 1.84, indicating that inflammatory stimulation significantly induced the activation of neurosensitivity-related pathways. The compositions of this invention (CM2-1, CM2-2, and CM2-3) significantly downregulated TRPV1 expression levels. Specifically, the CM2-1 and CM2-2 groups decreased to 0.82 and 0.82, respectively, essentially returning to normal cell levels, while the CM2-3 group also decreased to around 1.05. In contrast, the TRPV1 expression levels in the single-component A group, the single-component B group, and the CM2-4, CM2-5, and CM2-6 groups remained above 1.30. These results indicate that, under certain ratios, the aqueous extract of *Chimonanthus praecox* and dipotassium glycyrrhizate can synergistically regulate the expression of neurosensitivity-related receptors and downregulate inflammation-induced TRPV1 expression levels, which has a positive effect on relieving sensitivity symptoms such as stinging, burning, and neuropruritus.

[0207] (3) Inhibition effect on mast cell degranulation: Mast cell degranulation is a prerequisite for histamine release and an important mechanism for triggering skin itching, irritation, and allergic reactions. The rate of mast cell degranulation is used as an indicator to reflect the status of histamine release.

[0208] Figure 5 The results showed that the degranulation rate in the model group reached 74.93%, significantly higher than that in the blank control group. The compositions of this invention (CM2-1, CM2-2, and CM2-3) significantly reduced mast cell degranulation levels. Specifically, the degranulation rate in the CM2-1 group decreased to 44.45%, while that in the CM2-2 and CM2-3 groups decreased to 47.51% and 54.67%, respectively, all superior to single-component groups A and B, as well as groups CM2-4, CM2-5, and CM2-6. These results indicate that, under certain ratios, the aqueous extract of *Chimonanthus praecox* and dipotassium glycyrrhizate can synergistically inhibit mast cell activation, reduce the release of inflammatory and allergic mediators, thereby exerting good anti-allergic, antipruritic, and soothing effects.

[0209] In summary, the composition of this invention achieves a full-chain intervention from controlling the source of inflammation and blocking the inflammatory cascade to improving terminal sensitive symptoms through a multi-level synergistic mechanism of "ROS scavenging-inflammatory factor inhibition-NO / TRPV1 / mast cell regulation". Its overall activity is significantly superior to that of single-component groups A and B, as well as groups CM2-4, CM2-5, and CM2-6, indicating that under certain ratios, the aqueous extract of *Chimonanthus praecox* and dipotassium glycyrrhizate have a significant synergistic effect in multiple aspects of anti-inflammatory and soothing effects.

[0210] Test Example 3: Evaluation of anti-inflammatory and soothing effects in humans 3.1 Preparation methods of cosmetics This test case involves preparing different test substances into cosmetics and then evaluating their efficacy on human subjects. The preparation steps for the cosmetics are as follows: (1) Prepare materials according to the formula in Table 3 and mix the corresponding components to obtain phase A, phase B and phase C.

[0211] (2) Heat phase A and phase B to 85°C respectively until completely dissolved. Then add phase B to phase A and homogenize for 2 minutes. Stir and cool to 40°C, then add phase D and stir until homogeneous to obtain cosmetic.

[0212] Table 3 Cosmetic Formulations

[0213] 3.2 Skin barrier function: Transepidermal water loss (TEWL) detection 3.2.1 Detection Method Using the Tewameter skin moisture loss analyzer, with transepidermal water loss (TEWL) as the detection index, a total of 20 subjects were recruited. Before the experiment (D0), subjects were required to cleanse their faces half an hour in advance and keep their skin in a stable state. Then, the blank index of the experimental area was measured and defined. During the experiment, subjects were instructed to apply the blank sample to the left cheek and the test sample to the right cheek, once in the morning and once in the evening. The transepidermal water loss index (TEWL value) was measured again using the Tewameter skin moisture loss analyzer on the 7th day (D7), the 14th day (D14), and the 28th day (D28) to compare and analyze the skin care effect of the samples.

[0214] When the test substance is composition CM2-1, the transdermal water loss measured at different contents is shown in Table 4.

[0215] Table 4 Results of transdermal water loss detection

[0216] TEWL is an important indicator for evaluating skin barrier function; the lower the value, the better the skin barrier integrity. Table 4 shows that compared with the blank control group (cosmetics without the test substance), cosmetics containing CM2-1 showed a more significant TEWL decreasing trend at all test time points. After 28 days of continuous use, the TEWL of the blank control group decreased by only 18.18%, while the sample group containing 0.5% of the composition CM2-1 decreased by 53.10%, approximately 2.92 times that of the blank control group. This indicates that the composition of the present invention can significantly reduce skin moisture loss, improve the water-locking capacity of the stratum corneum, and promote skin barrier repair, and its improving effect continues to enhance with prolonged use.

[0217] 3.3 Anti-inflammatory and soothing effects: Erythema Index (EI) detection in the skin. 3.3.1 Detection Method Using the MX18 skin melanin and hemoglobin analyzer from Guangzhou Walker Trading Co., Ltd., with skin hemoglobin content (EI) as the detection indicator, a total of 60 subjects were recruited. Before the experiment (denoted as "D0"), subjects were required to cleanse their faces half an hour in advance and keep their skin in a stable state. Subsequently, the blank index of the experimental area was measured and delineated. During the experiment, subjects were instructed to apply the blank sample to the left cheek and the test sample to the right cheek, once in the morning and once in the evening. Skin hemoglobin content (EI value) was measured again on day 7 (denoted as "D7"), day 14 (denoted as "D14"), and day 28 (denoted as "D28"). The EI value is a quantitative indicator reflecting erythema on the skin surface (caused by inflammation, vasodilation, or allergic reaction). The higher the measured EI value, the higher the hemoglobin content.

[0218] Table 5 shows the effects of cosmetics on skin hemoglobin levels under different test substances and test substance concentrations.

[0219] Table 5 Results of skin hemoglobin content detection

[0220] EI values ​​reflect the skin's hemoglobin content and the degree of erythema; the lower the value, the milder the skin inflammation and telangiectasia. Table 5 shows: (1) After 28 days of continuous use, the EI value of the blank control group (cosmetics without the test substance) decreased by 8.47%, while the EI value of the sample group containing 0.5% composition CM2-1 / CM3 / CM4 decreased significantly more than that of the blank control group, indicating that the composition of the present invention has excellent anti-inflammatory and soothing ability and can effectively relieve skin vasodilation and inflammatory response caused by sensitive stimulation. In addition, the team of the present invention used the VISIA-CR facial image analysis system to perform high-precision red zone chromatographic imaging tracking of facial erythema index before and after continuous use of cosmetics containing composition CM2-1 (the content of composition CM2-1 in the cosmetics is 0.2wt%). The results ( Figure 6 The results showed that after 28 days of continuous use of cosmetics containing composition CM2-1, the red area on the side of the face was significantly reduced, the red signal intensity was significantly reduced, and the original continuous high-intensity erythema gradually turned into a scattered low-intensity light red area. At the same time, the microvascular dilation characteristics of the nasal wings and cheeks were significantly weakened, which also indicates that the composition of the present invention has excellent anti-inflammatory and soothing ability.

[0221] (2) Comparing the detection results of compositions CM2-1 and CM1 with those of single components CSE2, CSE1 and dipotassium glycyrrhizate, it can be seen that when conventional water extraction method is used, the prepared water extract of *Chimonanthus praecox* (CSE1) can produce a synergistic effect with dipotassium glycyrrhizate in anti-inflammatory and soothing aspects; while when the improved method of this invention is used to prepare water extract of *Chimonanthus praecox*, not only can the anti-inflammatory and soothing effects of the water extract of *Chimonanthus praecox* itself be improved, but the synergistic effect between it and dipotassium glycyrrhizate can also be further enhanced.

[0222] (3) Compared to composition CM5, the EI value decreased significantly when using cosmetics containing composition CM4, indicating that adding phytic acid for multivalent cation solidification during the preparation of the *Chimonanthus praecox* water extract can effectively improve the anti-inflammatory and soothing effects of the composition. The reason for this is that by adding phytic acid for multivalent cation solidification, phytic acid can chelate the Ca in *Chimonanthus praecox*. 2+ and Mg 2+ This protects the effective concentration of dipotassium glycyrrhizate and prevents Ca2+ poisoning. 2+ and Mg 2+ It undergoes a metathesis reaction with dipotassium glycyrrhizate to form an insoluble precipitate, which leads to the salting out and deactivation of the latter.

[0223] (4) Compared with composition CM6, the EI value decreased significantly when using cosmetics containing composition CM4, indicating that the addition of nonionic surfactants during the preparation of the water extract of *Chimonanthus praecox* can effectively improve the anti-inflammatory and soothing effects of the composition. The reason is that by introducing nonionic surfactants, on the one hand, the water extraction yield of hydrophobic anti-inflammatory flavonoids in *Chimonanthus praecox* can be increased through micellar solubilization during the extraction process; on the other hand, the nonionic surfactants are retained in the final product along with the extract, and when compounded with dipotassium glycyrrhizate in the subsequent process, the two can self-assemble to form thermodynamically more stable mixed micelles, reduce the critical micelle concentration of the system, further encapsulate and stabilize the hydrophobic anti-inflammatory flavonoids enriched by the water extraction, and improve the solubility and stability of the formulation.

[0224] (5) Compared with composition CM7, the EI value decreased significantly when using cosmetics containing composition CM4, indicating that the anti-inflammatory and soothing effects of the composition were weakened when the temperature of flash evaporation and alternating dual-frequency ultrasonic extraction was too high during the preparation of the water extract of *Chimonanthus praecox*. The reason is that when the temperature of flash evaporation and alternating dual-frequency ultrasonic extraction is too high, the phenolic hydroxyl conjugated double bonds of flavonoid glycosides cannot be completely preserved, which is not conducive to their accumulation with the pentacyclic triterpenoid skeleton of dipotassium glycyrrhizate after compounding, thus affecting the capture affinity of the composition for HMGB1 factor, resulting in a weakening of the synergistic effect of the composition through upstream signal interception and downstream TRPV1 receptor regulation.

[0225] (6) Compared with composition CM8, the EI value decreased significantly when using cosmetics containing composition CM4, indicating that the timing of adding phytic acid for polyvalent cation solidification during the preparation of the water extract of *Chimonanthus praecox* affects the anti-inflammatory and soothing effects of the composition. The reason is that adding phytic acid before CO2 saturation permeation allows CO2 to enter the cells more easily and chelates pro-oxidative metal ions, thus preventing the oxidation of polyphenols and flavonoids released from the cells. In addition, the anti-inflammatory and soothing effect of composition CM8 is even lower than that of CM5, which did not use phytic acid in the preparation of the water extract of *Chimonanthus praecox*. This may be because during the preparation of composition CM8, the cells were fully broken when phytic acid was added, and the anti-inflammatory and soothing active ingredients such as flavonoids and polyphenols had already dissolved. The chelating and acidic properties of phytic acid can non-selectively bind with these active ingredients and metal ions in the system, easily forming insoluble phytic acid-active ingredient complexes, which disrupt the original stable state of the extract and cause additional loss of effective anti-inflammatory components.

Claims

1. A skin anti-inflammatory and soothing composition, characterized in that, It includes a water extract of *Chimonanthus praecox* in a mass ratio of 1 to 3:1 and dipotassium glycyrrhizate; the water extract of *Chimonanthus praecox* is extracted from the leaves and / or stems of *Chimonanthus praecox*.

2. A method for preparing the composition according to claim 1, characterized in that, step include: Mix willow-leaf wintersweet powder with water and heat at 50-100℃ for 0.5-3 hours. After solid-liquid separation, concentrate and dry the resulting liquid to obtain willow-leaf wintersweet water extract, which is then mixed with dipotassium glycyrrhizate to obtain the composition.

3. A method for preparing the composition according to claim 1, characterized in that, step include: S1: Mix willow-leaf wax plum powder with water, add phytic acid for multivalent cation solidification; S2: Place the product from S1 in a sealed container, evacuate it, and then fill it with CO2 for saturated permeation; S3: Add a nonionic surfactant to the product of S2 and homogenize it; S4: The product of S3 was subjected to flash evaporation and alternating dual-frequency ultrasonic extraction at 75~80℃. After solid-liquid separation, the obtained liquid was concentrated and dried to obtain the water extract of willow-leaf wax plum, which was then mixed with dipotassium glycyrrhizate to obtain the composition.

4. The preparation method according to claim 3, characterized in that, In step S1, cellulase is added before, at the same time as, or after adding phytic acid; the amounts of phytic acid and cellulase are 0.15~0.25wt% and 0.4~0.6wt% of the willow-leaf wax plum powder, respectively.

5. The preparation method according to claim 3, characterized in that, In step S3, the nonionic surfactant includes alkyl glycosides and / or polyglycerol fatty acid esters, and the amount used is 0.2~0.4wt% of the mass of the willow-leaf wax plum powder; the homogenization speed is 18000~20000rpm, the time is 10~15min, and the temperature of the liquid is ≤30℃ during the process.

6. The preparation method according to claim 3, characterized in that, In step S2, the process of vacuuming followed by CO2 saturation permeation includes: vacuuming to -0.08 to -0.09 MPa, maintaining the pressure for 5 to 10 minutes, introducing CO2 to 1.2 to 1.5 MPa, and stirring at 35 to 40°C and 150 to 200 rpm for 30 to 60 minutes.

7. The preparation method according to claim 3, characterized in that, In step S4, before the flash evaporation, the product S3 is preheated. The preheating and flash evaporation process includes: placing the product S3 in a sealed container, pressurizing it to 0.6~0.8MPa, heating it to 45~50℃, maintaining it for 5~10min, and then simultaneously depressurizing and heating it. The pressure is depressurized to atmospheric pressure at 0.2~0.3MPa / s, and the temperature is raised to 75~80℃ within 2.5~3.5min. The duration of the alternating dual-frequency ultrasonic extraction is 20~30min, the ultrasonic frequency is 25~30kHz and 40~45kHz, the ultrasonic frequency is switched every 3~5s, and the ultrasonic power is 550~650W.

8. The use of the composition according to claim 1 or the composition prepared by the method according to any one of claims 2 to 8 in the preparation of anti-inflammatory and soothing skin preparations.

9. The application according to claim 8, characterized in that, The skin anti-inflammatory and soothing preparation is a cosmetic, wherein the content of the composition is 0.005~5wt%.

10. The application according to claim 8 or 9, characterized in that, The skin anti-inflammatory and soothing agent is a preparation for reducing the levels of IL-1β, TNF-α, IL-6 and IL-8, or a preparation for clearing ROS, or a preparation for inhibiting NO production, or a preparation for downregulating TRPV1 expression, or a preparation for reducing mast cell degranulation rate.

Images